ReviewCurrent oncology reports2019
Management of Adrenocortical Carcinoma.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 88 citations in OpenAlex.
- PD-1 Blockade in Advanced Adrenocortical Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Prevalence of venous extension in malignant adrenal neoplasia: beyond primary tumors and identification of a novel imaging sign.European radiology · 2026Observational
- Analysis of clinical and pathological characteristics of classic adrenocortical carcinoma.Scientific reports · 2026Article
- Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma.Journal of immunotherapy and precision oncology · 2025Article
- Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study.The oncologist · 2024Article
- Clinical and Pathological Predictors of Death for Adrenocortical Carcinoma.Journal of the Endocrine Society · 2024Article
- Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma.Annals of surgical oncology · 2024Article
- Surgical Management of Metastatic Adrenocortical Carcinoma.World journal of surgery · 2024Article
- Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy.European journal of medical research · 2023Article
- Article
- N7-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma.American journal of cancer research · 2023Article
- CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.Journal of translational medicine · 2022Article
- Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.Immunity, inflammation and disease · 2022Article
- Ferroptosis-based molecular prognostic model for adrenocortical carcinoma based on least absolute shrinkage and selection operator regression.Journal of clinical laboratory analysis · 2022Article
- EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report.Translational cancer research · 2022Article
- Article
- Functioning metastasis from adrenocortical carcinoma.BMJ case reports · 2022Article
- Review
- Antioxidant and antiradical activities depend on adrenal tumor type.Frontiers in endocrinology · 2022Article
- Identification and Verification of Immune-Related Genes Prognostic Signature Based on ssGSEA for Adrenocortical Carcinoma (ACC).International journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAdrenocortical carcinoma (ACC) is a rare endocrine malignancy typically with poor prognosis. This review aims to summarize the current knowledge regarding the clinical management of ACC. RECENT
findingsSurgery remains the cornerstone for localized ACC management. In more advanced cases, debulking surgery when feasible can help with hormonal control and may allow the initiation of systemic therapy. Over the last few years, our understanding of ACC molecular pathogenesis has expanded with no significant change in treatment options. Platinum-based chemotherapy is the gold standard in metastatic ACC despite suboptimal efficacy. Tyrosine kinase inhibitor use did not result in meaningful benefit in ACC patients. Multiple clinical trials are currently exploring the role of immunotherapy in ACC. Despite the remarkable improvement in our understanding of the molecular signature and pathways in ACC, this knowledge did not yield a major breakthrough in management of advanced ACC. Multi-institutional and international collaborations are needed to identify promising treatments and new therapeutic targets to improve the care of ACC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.